Cart
sales@molnova.com
Ac2-26 TFA (151988-33-9 free base)
CAS No.
Ac2-26 TFA (151988-33-9 free base) ( )
Catalog No. M30020 CAS No.
Ac2-26 TFA, an active N-terminal peptide of annexin A1 (AnxA1), attenuates ischemia-reperfusion-induced acute lung injury. Ac2-26 also decreases AnxA1 protein expression, inhibits the activation of NF-κB and MAPK pathways in the injured lung tissue.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
Biological Information
-
Product NameAc2-26 TFA (151988-33-9 free base)
-
NoteResearch use only, not for human use.
-
Brief DescriptionAc2-26 TFA, an active N-terminal peptide of annexin A1 (AnxA1), attenuates ischemia-reperfusion-induced acute lung injury. Ac2-26 also decreases AnxA1 protein expression, inhibits the activation of NF-κB and MAPK pathways in the injured lung tissue.
-
DescriptionAc2-26 TFA, an active N-terminal peptide of annexin A1 (AnxA1), attenuates ischemia-reperfusion-induced acute lung injury. Ac2-26 also decreases AnxA1 protein expression, inhibits the activation of NF-κB and MAPK pathways in the injured lung tissue.
-
Synonyms
-
PathwayOthers
-
TargetOther Targets
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number--
-
Formula Weight3203.5
-
Molecular FormulaC143H211F3N32O46S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
Liao WI, et al. Ac2-26, an Annexin A1 Peptide, Attenuates Ischemia-Reperfusion-Induced Acute Lung Injury. Int J Mol Sci. 2017 Aug 15;18(8). pii: E1771.
molnova catalog
related products
-
threo-Guaiacylglycer...
Threo-Guaiacylglycerol beta-coniferyl ether displays significant inhibitory effects on NO production.
-
Enterolactone
Enterolactone is a useful organic compound for research related to life sciences.
-
SJ6986
SJ6986 is a chemical probe for studying the role of GSPT1/2 in vitro and in vivo. SJ6986 supports the utility of a diverse library of CRBN binders in the pursuit of targeting undruggable oncoproteins.
